

Dear Recipient:

You have been identified as a potential class member in a securities class action involving Aegerion Pharmaceuticals, Inc. captioned *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, No. 1:14-cv-10105-MLW. Enclosed is a notice about the settlement of that class action lawsuit. You may be eligible to claim a payment from the settlement or you may want to act on other legal rights. Important facts are highlighted below and explained in the notice:

- **Security:** Aegerion Pharmaceuticals, Inc. common stock.
- **Time Period:** Aegerion Pharmaceuticals, Inc. stock bought from April 30, 2013 through and including May 11, 2016.
- **Settlement Amount:** \$22.25 million (the average distribution will be \$0.31 per share if claims are submitted for each share, before deductions for costs and attorneys' fees).
- **Reasons for Settlement:** Avoids costs and risks from continuing the lawsuit; avoids risks resulting from the present weak financial condition of Aegerion and the limited resources with which a settlement or judgment could be paid; releases defendants from liability.
- **If the Case had not Settled:** There would have been further litigation and possibly a trial. Plaintiffs estimated that they may have obtained a judgment as high as \$844.6 million, but acknowledge they may not have been able to collect on that judgment. The defendants think that plaintiffs would not have won anything from a trial.
- **Attorneys' Fees and Expenses:** Counsel for the Class will ask the Court for an award of attorneys' fees of 25% of the Settlement Amount, plus expenses not to exceed \$250,000. Each of the Class Representatives will seek reimbursement of their time and expenses in representing the Class in an amount not to exceed \$17,500 in the aggregate. The requested attorneys' fees and expenses amount to an average cost of approximately \$0.08 per share of Aegerion common stock included in the Class Period.
- **Deadlines:**
  - o **Claims:** November 17, 2017
  - o **Exclusions:** October 31, 2017
  - o **Objections:** October 31, 2017
  - o **Court Hearing on Fairness of Settlement:** November 30, 2017, at 2:00 p.m. ET
- **More Information:** You may contact the Claims Administrator toll-free at 1-844-319-2120, or visit [www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com). You may also contact representatives of counsel for the Class:

Rick Nelson, Shareholder Relations  
Robbins Geller Rudman & Dowd LLP  
655 West Broadway, Suite 1900  
San Diego, CA 92101  
1-800-449-4900

Gregg S. Levin, Christopher F. Moriarty  
Motley Rice LLC  
28 Bridgeside Blvd.  
Mt. Pleasant, SC 29464  
1-843-216-9000

Get more details in the enclosed Notice from the United States District Court for the District of Massachusetts.

**TO: ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED COMMON STOCK OF AGERION PHARMACEUTICALS, INC. (“AEGERION” OR THE “COMPANY”) DURING THE PERIOD FROM APRIL 30, 2013 THROUGH AND INCLUDING MAY 11, 2016 (THE “CLASS PERIOD”)**

A FEDERAL COURT AUTHORIZED THIS NOTICE. THIS IS NOT A SOLICITATION FROM A LAWYER.

THE COURT HAS RETAINED THE DISCRETION TO ALTER ANY OF THE DEADLINES AND REQUIREMENTS SET FORTH HEREIN FOR GOOD CAUSE SHOWN.

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THIS ACTION. PLEASE NOTE THAT IF YOU ARE A CLASS MEMBER, YOU MAY BE ENTITLED TO SHARE IN THE PROCEEDS OF THE SETTLEMENT DESCRIBED IN THIS NOTICE. TO CLAIM YOUR SHARE OF THE SETTLEMENT PROCEEDS, YOU MUST SUBMIT A VALID PROOF OF CLAIM AND RELEASE FORM (“PROOF OF CLAIM”) **POSTMARKED (IF MAILED) OR RECEIVED (IF SUBMITTED ONLINE) ON OR BEFORE NOVEMBER 17, 2017.**

The purpose of this Notice is to inform you of (i) the pendency of this class action (the “Litigation”) between Lead Plaintiffs KBC Asset Management NV, Sheet Metal Workers’ National Pension Fund, and Chester County Employees’ Retirement Fund (“Lead Plaintiffs”) and Defendants Aegerion, Marc D. Beer, Craig Fraser, and Mark J. Fitzpatrick (“Defendants”); (ii) the proposed \$22.25 million settlement reached therein (the “Settlement”); and (iii) the hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, the proposed Plan of Allocation, and Lead Counsel’s application for fees, costs, and expenses (which will include Lead Plaintiffs’ reimbursement for their time and expenses representing the Class). This Notice describes what steps you may take in relation to the Settlement and this class action.<sup>1</sup>

<b>YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT</b>	
<b>SUBMIT A PROOF OF CLAIM FORM</b>	The only way to be eligible to receive a payment from the Settlement. Unless otherwise extended by the Court, <b>Proof of Claim forms must be postmarked (if mailed) or received (if submitted online) on or before November 17, 2017.</b>
<b>EXCLUDE YOURSELF</b>	Get no payment. This is the only option that <i>potentially</i> allows you to ever be part of any other lawsuit against the Defendants or any other Released Persons about the legal claims being resolved by this Settlement. Unless otherwise extended by the Court, <b>exclusions must be postmarked on or before October 31, 2017.</b>
<b>OBJECT</b>	Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or the request for attorneys’ fees and expenses. You will still be a Member of the Class. Unless otherwise extended by the Court, <b>objections must be received by the Court and counsel for the Settling Parties on or before October 31, 2017.</b>
<b>GO TO THE HEARING ON NOVEMBER 30, 2017 AT 2:00 P.M. ET</b>	Ask to speak in Court about the fairness of the Settlement. Unless otherwise extended by the Court, <b>requests to speak must be received by the Court and counsel for the Settling Parties on or before October 31, 2017.</b>
<b>DO NOTHING</b>	Receive no payment. You will, however, still be a Member of the Class, which means that you give up your right to ever be part of any other lawsuit against the Defendants or any other Released Persons about the legal claims being resolved by this Settlement and you will be bound by any judgments or orders entered by the Court in the Litigation.

**SUMMARY OF THIS NOTICE**

**The Nature of this Lawsuit**

The Litigation is pending before the Honorable Mark L. Wolf in the United States District Court for the District of Massachusetts (the “Court”). The initial complaint in this action was filed on January 15, 2014. Lead Plaintiffs allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by, among other things, issuing false and misleading statements and/or failing to disclose that: (i) despite asserting their compliance with FDA rules and regulations, in order to achieve and maintain profitability, Defendants illegally marketed JUXTAPID beyond its FDA-approved label; (ii) the Company was experiencing a higher than expected drop-out rate for JUXTAPID; (iii) more patients than expected were not filling their JUXTAPID prescriptions; and (iv) issues existed relating to the performance of, or the potential market for, JUXTAPID, including, but not limited to, statements and omissions of information necessary for investors to understand that JUXTAPID was not performing and could not

<sup>1</sup> All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings provided in the Stipulation of Settlement dated January 17, 2017 (the “Stipulation”), which is available on the website [www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com).

lawfully perform as well in the market as the Defendants' statements and omissions led the public to believe. Lead Plaintiffs further allege that the drop-out rate and patient-elected non-starts were key metrics that Aegerion utilized to forecast its annual revenue guidance.

### **Statement of Class Recovery**

Pursuant to the Settlement described herein, a \$22.25 million settlement fund has been established. Based on Lead Plaintiffs' estimate of the number of shares of Aegerion common stock damaged during the Class Period, the average distribution per share under the Plan of Allocation is roughly \$0.31 per share before deduction of any taxes on the income earned on the Settlement Amount, notice and administration costs, and allowable attorneys' fees and expenses as determined by the Court. **These are only estimates, however.** A Class Member's actual recovery will be a proportion of the Net Settlement Fund determined by that claimant's claims as compared to the total claims of all Class Members who submit acceptable Proofs of Claim. An individual Class Member may receive more or less than this estimated average amount, depending on the number of claims submitted, when during the Class Period a Class Member purchased or acquired Aegerion common stock, the purchase price paid, and whether those shares were held at the end of the Class Period or sold during the Class Period, and, if sold, when they were sold and the amount received. See Plan of Allocation set forth and discussed at pages 9-11 below for more information on the calculation of your claim.

### **Statement of Potential Outcome of Case**

The Settling Parties disagree on both liability and damages and do not agree on the amount of damages that would be recoverable if the Class prevailed on each claim alleged. Defendants deny that they are liable to the Class and deny that the Class has suffered any damages. The issues on which the parties disagree are many, but include: (1) whether Defendants engaged in conduct that would give rise to any liability to the Class under the federal securities laws, or any other laws; (2) whether Defendants have valid defenses to any such claims of liability; (3) the appropriate economic model for determining the amount by which the price of Aegerion common stock was allegedly artificially inflated (if at all) during the Class Period; (4) the amount, if any, by which the price of Aegerion common stock was allegedly artificially inflated (if at all) during the Class Period; (5) the effect of various market forces on the price of Aegerion common stock at various times during the Class Period; (6) the extent to which external factors influenced the price of Aegerion common stock at various times during the Class Period; (7) the extent to which the various matters that Lead Plaintiffs alleged were materially false or misleading influenced (if at all) the price of Aegerion common stock at various times during the Class Period; and (8) the extent to which the various allegedly adverse material facts that Lead Plaintiffs alleged were omitted influenced (if at all) the price of Aegerion common stock at various times during the Class Period. A consultant retained by counsel for Plaintiffs has opined that, if Lead Plaintiffs prevailed on all of their claims, recoverable damages could be as high as \$844.6 million, an amount which Defendants dispute.

### **Reasons for the Settlement**

Lead Plaintiffs' principal reason for entering into the Settlement is the benefit to the Class now, without further risk or the delays inherent in continued litigation. The cash benefit under the Settlement must be considered against the significant risk that a smaller recovery – or, indeed, no recovery at all – might be achieved after contested motions, trial, and likely appeals, a process that could last several years into the future. Those risks include the present financial condition of Aegerion, the limited insurance proceeds, the resources of the Individual Defendants, and Aegerion's financial obligations under its Settlement Agreement with the U.S. Department of Justice and the U.S. Securities and Exchange Commission. Lead Plaintiffs have therefore concluded that the proposed Settlement is fair, reasonable and adequate to Members of the Class. On November 29, 2016, Aegerion and QLT Inc. ("QLT") merged, with Aegerion becoming an indirect wholly owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name to Novelon Therapeutics Inc. ("Novelon"). Under the terms of the merger, however, Novelon is not responsible for any liability of Defendants to the Class, and the Class cannot access any of Novelon's assets.

Moreover, at the time of entering into the Settlement, Aegerion's prospects for continuing as a going concern were questioned by its outsider auditor, Ernst & Young LLP ("E&Y"). See Aegerion Pharms., Inc., Quarterly Report (Form 10-Q) (Aug. 9, 2016) at 96 (noting E&Y's "substantial doubt" about Aegerion's ability to continue as a going concern in its report for year-end 2015). If Aegerion were to enter bankruptcy, the Class would only have a remote chance of eventually obtaining any recovery. In this regard, from December 31, 2015 to June 30, 2016, Aegerion's available cash fell from \$64 million to \$46 million. *Id.* at 4. Aegerion's financial situation was such that it needed to arrange a \$15 million "lifeline" loan with QLT. Absent such a loan, Aegerion stated that it "would need to raise capital or obtain alternative financing to . . . fund our operations," or it would be forced to "delay, reduce or cease operations." *Id.* at 109. Aegerion also projected that it would have a negative net income of \$130 million in 2016 and a negative net income of \$53 million in 2017. See QLT Inc., Registration Statement (Form S-4) (Aug. 8, 2016) at 80.

Further depleting the available resources available to the Class, Aegerion carries substantial debts and obligations, including \$325 million in convertible notes that come due in 2019 and \$40 million payable over three years

to the U.S. Department of Justice and the U.S. Securities and Exchange Commission as part of the resolution of certain investigations that had been conducted by those agencies.

Finally, the insurance proceeds available to cover the claims in this Litigation are limited, further reducing the amount available to the Class. The longer the litigation continued, the more the available insurance proceeds would have been reduced, including the possibility that all available insurance policies would have been exhausted before any verdict or later settlement.

For Defendants, who have denied and continue to deny all allegations of liability, fault, or wrongdoing whatsoever in connection with this matter, the principal reason for entering into the Settlement is to eliminate the uncertainty, risk, costs, and burdens inherent in any litigation, especially in complex cases such as this action. Defendants have concluded that further litigation could be protracted and distracting.

Under these circumstances, and given the complex and highly uncertain nature of proceeding with the action and eventually trying this case before a jury, Lead Plaintiffs submit that the resolution of the Litigation for \$22,250,000 is an excellent result for the Class.

#### **Statement of Attorneys' Fees and Expenses Sought**

Lead Counsel will apply to the Court for an award of attorneys' fees of twenty-five percent (25%) of the Settlement Amount, plus expenses not to exceed \$250,000, plus interest earned on both amounts at the same rate as earned by the Settlement Fund. Since the Litigation's inception, Lead Plaintiffs' Counsel have expended considerable time and effort in the prosecution of this Litigation on a wholly contingent basis and have advanced the expenses of the Litigation in the expectation that if they were successful in obtaining a recovery for the Class, they would be paid from such recovery. In addition, as part of that application, each of the Lead Plaintiffs will seek reimbursement of their time and expenses in representing the Class in an amount not to exceed \$17,500 in the aggregate. The requested attorneys' fees and expenses amount to an average cost of approximately \$0.08 per allegedly damaged share of Aegerion common stock.

#### **Further Information**

For further information regarding the Litigation, this Notice or to review the Stipulation, please contact the Claims Administrator toll-free at 1-844-319-2120, or visit the website [www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com). Additionally, documents related to the Settlement and this case will be posted on the website.

You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, [www.rgrdlaw.com](http://www.rgrdlaw.com) or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

**Please Do Not Call the Court or Defendants with Questions About the Settlement.**

### **BASIC INFORMATION**

#### **1. Why did I get this notice package?**

This Notice was sent to you pursuant to an Order of a U.S. Federal Court because you or someone in your family or an investment account for which you serve as custodian may have purchased or otherwise acquired Aegerion publicly traded common stock during the period from April 30, 2013, through and including May 11, 2016 ("Class Period").

This Notice explains the class action lawsuit, the Settlement, Class Members' legal rights in connection with the Settlement, what benefits are available, who is eligible for them, and how to get them.

The Court in charge of the Litigation is the United States District Court for the District of Massachusetts, and the case is known as *KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al.*, Case No. 1:14-cv-10105-MLW. The case has been assigned to the Honorable Mark L. Wolf. The parties representing the Class are the "Lead Plaintiffs," and the company and individuals they sued and who have now settled are called the Defendants.

#### **2. What is this lawsuit about?**

The Litigation is pending before the Honorable Mark L. Wolf in the United States District Court for the District of Massachusetts (the "Court"). The initial complaint in this action was filed on January 15, 2014. Lead Plaintiffs allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by, among other things, issuing false and misleading statements and/or failing to disclose that: (i) despite asserting their compliance with FDA rules and regulations, in order to achieve and maintain profitability, Defendants illegally marketed JUXTAPID beyond its FDA-approved label; (ii) the Company was experiencing a higher than expected drop-out rate for JUXTAPID; (iii) more patients than expected were not filling their JUXTAPID prescriptions; and (iv) issues existed relating to the performance of, or the potential market for, JUXTAPID, including, but not limited to, statements and

omissions of information necessary for investors to understand that JUXTAPID was not performing and could not lawfully perform as well in the market as the Defendants' statements and omissions led the public to believe. Lead Plaintiffs further allege that the drop-out rate and patient-elected non-starts were key metrics that Aegerion utilized to forecast its annual revenue guidance.

On June 1, 2015, Lead Plaintiffs filed their Amended Class Action Complaint ("Amended Complaint"). On July 31, 2015, Defendants filed their Motion to Dismiss the Amended Complaint. On August 21, 2015, Lead Plaintiffs filed their Second Amended Class Action Complaint ("Second Amended Complaint"). Defendants, on September 4, 2015, moved to strike the Second Amended Complaint. Lead Plaintiffs filed their opposition to the Motion to Strike on September 18, 2015.

Following oral argument on Defendants' Motion to Strike the Second Amended Complaint and Lead Plaintiffs' Motion for Leave to File the Second Amended Complaint, the Court entered an order requiring the parties to, among other things, confer and "report whether they have reached an agreement to permit or withdraw the lead plaintiffs' Second Amended Complaint." The parties thereafter conferred but were unable to reach an agreement, and informed the Court that Lead Plaintiffs would file an opposition to the Motion to Dismiss the Amended Complaint.

Following Aegerion's May 12, 2016 announcement that it had reached preliminary agreements in principle with the U.S. Department of Justice and the staff of the U.S. Securities and Exchange Commission regarding a settlement of the ongoing investigations by these agencies into the Company's sales activities and disclosures related to JUXTAPID, the parties conferred and reached an agreement for Lead Plaintiffs to file their Third Amended Class Action Complaint ("Third Amended Complaint"), which would extend the putative Class Period to April 30, 2013 through May 11, 2016, inclusive. Lead Plaintiffs filed the Third Amended Complaint on June 27, 2016.

In an effort to conserve judicial recovery and attempt to settle the Litigation, the parties engaged the services of the Hon. Daniel Weinstein (Ret.) and Jed Melnick, Esq. of JAMS, nationally recognized mediators. The parties prepared detailed mediation statements and engaged in a full-day in-person mediation session on November 14, 2016. These efforts culminated with the parties agreeing on November 29, 2016, to settle the Litigation for \$22,250,000, subject to the negotiation of the terms of a Stipulation of Settlement and approval by the Court.

**3. Why is there a settlement?**

The Court has not decided in favor of Defendants or in favor of Lead Plaintiffs. Instead, both sides agreed to the Settlement to avoid the distraction, costs, and risks of further litigation, and Lead Plaintiffs agreed to the Settlement in order to ensure that Class Members will receive compensation, particularly in light of Aegerion's precarious financial condition and the limited resources of the Defendants.

**WHO IS IN THE SETTLEMENT**

**4. How do I know if I am a Member of the Class?**

The Court directed that everyone who fits this description is a Class Member: ***all Persons who purchased or otherwise acquired Aegerion publicly traded common stock during the period from April 30, 2013, through and including May 11, 2016***, except those Persons and entities that are excluded.

Excluded from the Class are: Defendants, the officers and directors of Aegerion during the Class Period, members of their immediate families and their legal representatives, heirs, successors or assigns, and any entity in which Defendants have or had a controlling interest. Also excluded from the Class is any Class Member who timely and validly excludes themselves therefrom by submitting a request for exclusion in accordance with the requirements set forth in question 11 below.

**Please Note:** Receipt of this Notice does not mean that you are a Class Member or that you will be entitled to receive a payment from the Settlement. If you are a Class Member and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are required to submit the Proof of Claim that is being distributed with this Notice and the required supporting documentation as set forth therein postmarked or submitted online on or before November 17, 2017.

**5. What if I am still not sure if I am included?**

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator toll-free at 1-844-319-2120, or you can fill out and return the Proof of Claim form enclosed with this Notice package, to see if you qualify.

**THE SETTLEMENT BENEFITS – WHAT YOU GET**

**6. What does the Settlement provide?**

The Settlement provides that, in exchange for the release of the Released Claims (defined below) and dismissal of the Litigation, Defendants have agreed to pay (or cause to be paid) \$22.25 million in cash to be distributed

after taxes, fees, and expenses, *pro rata*, to Class Members who send in or submit a valid Proof of Claim form pursuant to the Court-approved Plan of Allocation. The Plan of Allocation is described in more detail at the end of this Notice.

**7. How much will my payment be?**

Your share of the Net Settlement Fund will depend on several things, including the total amount of claims represented by the valid Proof of Claim forms that Class Members send in or submit, compared to the amount of your claim, all as calculated under the Plan of Allocation discussed below.

**HOW YOU GET A PAYMENT – SUBMITTING A CLAIM FORM**

**8. How can I get a payment?**

To be eligible to receive a payment from the Settlement, you must submit a Proof of Claim form. A Proof of Claim form is enclosed with this Notice or it may be downloaded at [www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com). Read the instructions carefully, fill out the Proof of Claim, include all the documents the form asks for, sign it, and **mail or submit it online so that it is postmarked (if mailed) or received (if submitted online) no later than November 17, 2017**. The Proof of Claim form may be submitted online at [www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com).

**9. When would I get my payment?**

**The Court will hold a Settlement Hearing on November 30, 2017, at 2:00 p.m. ET**, to decide whether to approve the Settlement. If the Court approves the Settlement, there might be appeals. It is always uncertain whether appeals can be resolved, and if so, how long it would take to resolve them. It also takes time for all the Proofs of Claim to be processed. Please be patient.

**10. What am I giving up to get a payment or to stay in the Class?**

Unless you timely and validly exclude yourself, you are staying in the Class, and that means you cannot sue, continue to sue, or be part of any other lawsuit against Defendants or their Related Parties about the Released Claims (as defined below) in this case. It also means that all of the Court's orders will apply to you and legally bind you. If you remain a Class Member, and if the Settlement is approved, you will give up all "Released Claims" (as defined below), including "Unknown Claims" (as defined below), against the "Released Persons" (as defined below):

- "Released Claims" means any and all claims, rights, duties, controversies, obligations, demands, actions, debts, sums of money, suits, contracts, agreements, promises, damages, losses, judgments, liabilities, allegations, arguments and causes of action of every nature and description, whether known or unknown, whether arising under federal, state, local, common, statutory, administrative, or foreign law, or any other law, rule or regulation, at law or in equity, whether class or individual in nature, whether direct or derivative, whether fixed or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, whether matured or unmatured, which arise out of or relate in any way to both: (i) the purchase or acquisition of shares of Aegerion publicly traded common stock during the Class Period, and (ii) the acts, facts, statements, or omissions that were or could have been alleged by Lead Plaintiffs or any Class Member in the Litigation. "Released Claims" does not include claims to enforce the Settlement. "Released Claims" includes "Unknown Claims" as defined below.
- "Released Defendants' Claims" means any and all claims, rights, duties, controversies, obligations, demands, actions, debts, sums of money, suits, contracts, agreements, promises, damages, losses, judgments, liabilities, allegations, arguments, and causes of action of every nature and description (including Unknown Claims), whether arising under federal, state, local, common, statutory, administrative, or foreign law, or any other law, rule or regulation, at law or in equity, that arise out of or relate in any way to the institution, prosecution or settlement of the claims against Defendants in the Litigation, except for claims relating to the enforcement of the Settlement.
- "Released Persons" means each and all of the Defendants and their Related Parties.
- "Related Parties" means each of a Defendant's respective former, present or future parents, subsidiaries, divisions and affiliates and the respective present and former employees, members, partners, principals, officers, directors, controlling shareholders, attorneys, advisors, accountants, auditors, and insurers and reinsurers of each of them; and the predecessors, successors, estates, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives and assigns of each of them, in their capacity as such.
- "Unknown Claims" means any and all Released Claims or Released Defendants' Claims that any of the Settling Parties or Class Members do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class

Members which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members, or might have affected his, her, or its decision(s) with respect to the Settlement, including, but not limited to, whether or not to object to this Settlement or to the release of the Released Persons, Lead Plaintiffs, Lead Plaintiffs' Counsel, or Class Members. With respect to any and all Released Claims and Released Defendants' Claims, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each of the Settling Parties shall be deemed to have, and by operation of the Judgment shall have, expressly waived the provisions, rights, and benefits of California Civil Code §1542, which provides:

**A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.**

The Settling Parties shall expressly waive and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable or equivalent to California Civil Code §1542. The Settling Parties acknowledge that they may hereafter discover facts in addition to or different from those which he, she, it or their counsel now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but the Settling Parties shall expressly settle and release, and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims and Released Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and the Class Members shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement of which this release is a part.

#### **EXCLUDING YOURSELF FROM THE CLASS**

If you do not want to participate in this Settlement, and you want to keep the right to potentially sue the Defendants and the other Released Persons, on your own, about the claims being released by the Settlement, then you must take steps to remove yourself from the Class. This is called excluding yourself – or is sometimes referred to as “opting out.”

#### **11. How do I opt out of the Class and the proposed Settlement?**

To exclude yourself from the Class and the Settlement, you must send a letter by First-Class Mail stating that you “request exclusion from the Class in the *Aegerion Securities Litigation*.” You **cannot** exclude yourself by telephone or e-mail. Your letter must include your purchases, acquisitions, and sales of Aegerion publicly traded common stock during the Class Period, including the dates, the number of shares of Aegerion publicly traded common stock you purchased, acquired, or sold, and price paid or received for each such purchase, acquisition, or sale. In addition, you must include your name, address, telephone number, and your signature. Unless otherwise extended by the Court, you must submit your exclusion request so that it is **postmarked no later than October 31, 2017** to:

*Aegerion Securities Litigation*  
Claims Administrator  
EXCLUSIONS  
c/o Gilardi & Co. LLC  
3301 Kerner Blvd.  
San Rafael, CA 94901

Unless otherwise altered by Order of the Court, your exclusion request must comply with the above requirements in order to be valid. If you ask to be excluded, you will not receive any payment from the Settlement, and you cannot object to the Settlement. You will not be legally bound by anything that happens in this lawsuit, and you may be able to sue the Defendants and the other Released Persons about the Released Claims in the future.

**12. If I do not exclude myself, can I sue the Defendants and the other Released Persons for the same thing later?**

No. Unless you exclude yourself, you give up any rights you may potentially have to sue the Defendants and the other Released Persons for any and all Released Claims. If you have a pending lawsuit against the Released Persons, speak to your lawyer in that case immediately. You must exclude yourself from the Class in this Litigation to continue your own lawsuit. Remember, the exclusion deadline is October 31, 2017.

**13. If I exclude myself, can I get money from the proposed Settlement?**

No. If you exclude yourself, you should not send in a Proof of Claim to ask for any money. But, if you do exclude yourself, you may have the right to potentially sue or be part of a different lawsuit against the Defendants and the other Released Persons.

**THE LAWYERS REPRESENTING YOU**

**14. Do I have a lawyer in this case?**

The Court ordered that the law firms of Robbins Geller Rudman & Dowd LLP and Motley Rice LLC represent the Class Members, including you. These lawyers are called Lead Counsel. If you want to be represented by your own lawyer, you may hire one at your own expense.

**15. How will the lawyers be paid?**

Lead Counsel will apply to the Court for an award of attorneys' fees of twenty-five percent (25%) of the Settlement Amount and for expenses and costs in an amount not to exceed \$250,000 in connection with the Litigation, plus interest on such fees and expenses at the same rate as earned by the Settlement Fund. In addition, one or more of the Lead Plaintiffs will seek reimbursement for their time and expenses incurred in representing the Class in an amount not to exceed \$17,500 in the aggregate. Such sums as may be approved by the Court will be paid from the Settlement Fund.

**OBJECTING TO THE SETTLEMENT**

You can tell the Court that you do not agree with the Settlement or any part of it.

**16. How do I tell the Court that I object to the proposed Settlement?**

If you are a Class Member, you can comment or object to the proposed Settlement, the proposed Plan of Allocation, Lead Counsel's fee and expense application, and/or Lead Plaintiffs' time and expense request. You can write to the Court setting out your comment or objection. The Court will consider your views. To comment or object, you must send a signed letter saying that you wish to comment on or object to the proposed Settlement in the *Aegerion Securities Litigation*. Include your name, address, daytime telephone number, e-mail address, and your signature, identify the date(s), price(s), and number(s) of shares of Aegerion publicly traded common stock you purchased, acquired, and sold during the Class Period, and state your comments or the reasons why you object to the proposed Settlement, Plan of Allocation and/or fee and expense application. You must also include copies of documents demonstrating such purchase(s), acquisition(s) and/or sale(s). Unless otherwise extended by Order of the Court, your comments or objection must be filed with the Court and mailed or delivered to each of the following addresses such that it is **received no later than October 31, 2017**:

<b>COURT</b>	<b>LEAD COUNSEL</b>	<b>DEFENDANTS' COUNSEL</b>
U.S. DISTRICT COURT DISTRICT OF MASS. John Joseph Moakley U.S. Courthouse 1 Courthouse Way, Suite 2300 Boston, MA 02210	Ellen Gusikoff Stewart ROBBINS GELLER RUDMAN & DOWD LLP 655 West Broadway Suite 1900 San Diego, CA 92101	Randall W. Bodner ROPES & GRAY LLP Prudential Tower 800 Boylston Street Boston, MA 02199-3600

**17. What is the difference between objecting and excluding?**

Objecting is simply telling the Court that you do not like something about the Settlement. You can object **only** if you stay in the Class.

Excluding yourself is telling the Court that you do not want to be paid and do not want to release any claims you think you may have against Defendants and their Related Parties. If you exclude yourself, you cannot object to the Settlement because it does not affect you.



## THE COURT'S SETTLEMENT HEARING

The Court will hold a hearing to decide whether to approve the proposed Settlement. You may attend and you may ask to speak, but you do not have to.

### 18. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold a Settlement Hearing at **2:00 p.m. ET, on November 30, 2017**, in the Courtroom of the Honorable Mark L. Wolf, at the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210. At the hearing, the Court will consider whether the Settlement and the Plan of Allocation are fair, reasonable, and adequate. If there are objections, the Court will consider them, even if you do not ask to speak at the hearing. The Court will listen to people who attend the hearing. The Court may also issue a ruling on Lead Counsel's application for attorneys' fees and expenses (which request will include an application for reimbursement for Lead Plaintiffs' time and expenses in representing the Class in an amount not to exceed \$17,500 in the aggregate). After the Settlement Hearing, the Court will decide whether to approve the Settlement and the Plan of Allocation. We do not know how long these decisions will take. You should be aware that the Court may change the date and time of the Settlement Hearing without another notice being sent to Class Members. If you want to attend the hearing, you should check with Lead Counsel or the Settlement website [www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com) beforehand to be sure that the date and/or time has not changed.

### 19. Do I have to come to the hearing?

No. Lead Counsel will answer questions the Court may have. But, you are welcome to come at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but that is not necessary. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

### 20. May I speak at the hearing?

If you object to the Settlement, the Plan of Allocation, or the fee and expense application, you may ask the Court for permission to speak at the Settlement Hearing. To do so, you must include with your objection (see question 16 above) a statement saying that it is your "Notice of Intention to Appear in the *Aegerion Securities Litigation*." Persons who intend to object to the Settlement, the Plan of Allocation, and/or any attorneys' fees and expenses to be awarded to Lead Counsel (including any reimbursement to Lead Plaintiffs for their time and expenses representing the Class) and desire to present evidence at the Settlement Hearing must include in their written objections the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Settlement Hearing. Unless otherwise extended by an Order of the Court, your notice of intention to appear must be **received** no later than October 31, 2017, and addressed to the Clerk of Court, Lead Counsel, and Defendants' counsel, at the addresses listed above in question 16.

You cannot speak at the hearing if you exclude yourself from the Class.

### IF YOU DO NOTHING

### 21. What happens if I do nothing?

If you do nothing, you will not receive any money from this Settlement. In addition, unless you exclude yourself, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants and their Related Parties about the Released Claims in this case.

### GETTING MORE INFORMATION

### 22. How do I get more information?

For even more detailed information concerning the matters involved in this Litigation, you can obtain answers to common questions regarding the proposed Settlement by contacting the Claims Administrator toll-free at 1-844-319-2120. Reference is also made to the Stipulation, to the pleadings in support of the Settlement, to the Orders entered by the Court, and to the other settlement-related papers filed in the Litigation, which are posted on the Settlement website at [www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com), and which may be inspected at the Office of the Clerk of the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Suite 2300, Boston, MA 02210, during regular business hours. For a fee, all papers filed in this Litigation are available at [www.pacer.gov](http://www.pacer.gov).

You may also contact representatives of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, [www.rgrdlaw.com](http://www.rgrdlaw.com) or Gregg S. Levin, Christopher F. Moriarty, Motley Rice LLC, 28 Bridgeside Blvd., Mt. Pleasant, SC 29464, 1-843-216-9000.

**PLAN OF ALLOCATION OF NET SETTLEMENT FUND AMONG  
CLASS MEMBERS**

The Settlement Amount of \$22.25 million and any interest earned thereon is the “Settlement Fund.” The Settlement Fund, less all taxes, approved costs, fees, and expenses (the “Net Settlement Fund”) shall be distributed to Class Members who submit timely and valid Proof of Claim forms to the Claims Administrator (“Authorized Claimants”). The Plan of Allocation provides that you will be eligible to participate in the distribution of the Net Settlement Fund only if you have an overall net loss on all of your transactions in Aegerion publicly traded common stock during the Class Period.

For purposes of formulating the Plan of Allocation and determining the amount an Authorized Claimant may recover under it, Lead Counsel have conferred with their damages consultant regarding the Plan of Allocation and it reflects an assessment of the damages that they believe could have been recovered by Class Members had Lead Plaintiffs prevailed at trial.

In the unlikely event there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant’s claim, as defined below. If, however, and as is more likely, the amount in the Net Settlement Fund is not sufficient to permit payment of the total claim of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant’s claim bears to the total of the claims of all Authorized Claimants. Payment in this manner shall be deemed conclusive against all Authorized Claimants. Allowed claims will also be subjected to the statutory 90-day look-back amount provided for in the Private Securities Litigation Reform Act of 1995 (“PSLRA”).<sup>2</sup>

The calculation of claims below is not an estimate of the amount you will receive. It is a formula for allocating the Net Settlement Fund among all Authorized Claimants. Furthermore, if any of the formulas set forth below yield an amount less than or equal to \$0.00, the claim per share shall be \$0.00.

A “claim” will be calculated as follows:

**Aegerion Securities Litigation**  
**CUSIP: 00767E102**  
**April 30, 2013 – May 11, 2016**

The Plan of Allocation is based on the following chart setting forth alleged inflation per share amounts for Class Period common stock purchases, acquisitions, and sales and also takes into account the mean trading price of Aegerion common stock during the PSLRA 90-day look-back period (which was \$1.60).

<b>Inflation Period</b>	<b>Alleged Inflation per Share</b>
April 30, 2013 – January 9, 2014	\$36.21
January 10, 2014 – May 6, 2014	\$27.21
May 7, 2014 – October 30, 2014	\$18.02
October 31, 2014 – July 5, 2015	\$4.05
July 6, 2015 – November 9, 2015	\$2.85
November 10, 2015 – May 11, 2016	\$0.35
May 12, 2016 – thereafter	\$0.00

For shares of Aegerion common stock ***purchased, or acquired, on or between April 30, 2013 through May 11, 2016***, the recovery per share shall be as follows:

- a) If sold on or between April 30, 2013 through May 11, 2016, the recovery per share shall be the lesser of: (i) the inflation per share at the time of purchase or acquisition less the inflation per share at the time of sale; and (ii) the difference between the purchase or acquisition price and the selling price.
- b) If retained beyond May 11, 2016 and sold on or before August 9, 2016, the recovery per share shall be the least of: (i) the inflation per share at the time of purchase or acquisition; (ii) the difference between the purchase or acquisition price and the selling price; and (iii) the difference between the purchase or acquisition price and the average closing price up to the date of sale as set forth in the table below.

<sup>2</sup> Pursuant to Section 21D(e)(1) of the PSLRA, “in any private action arising under this chapter in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market.”

- c) If retained at the close of trading on August 9, 2016, or sold thereafter, the recovery per share shall be the lesser of: (i) the inflation per share at the time of purchase or acquisition; and (ii) the difference between the purchase or acquisition price and \$1.60.

Date	Closing Price	Average Closing Price
5/12/2016	\$1.91	\$1.91
5/13/2016	\$1.73	\$1.82
5/16/2016	\$2.31	\$1.98
5/17/2016	\$1.89	\$1.96
5/18/2016	\$1.78	\$1.92
5/19/2016	\$1.67	\$1.88
5/20/2016	\$1.73	\$1.86
5/23/2016	\$1.64	\$1.83
5/24/2016	\$1.64	\$1.81
5/25/2016	\$1.61	\$1.79
5/26/2016	\$1.73	\$1.79
5/27/2016	\$1.82	\$1.79
5/31/2016	\$1.78	\$1.79
6/1/2016	\$1.93	\$1.80
6/2/2016	\$1.76	\$1.80
6/3/2016	\$1.71	\$1.79
6/6/2016	\$1.78	\$1.79
6/7/2016	\$1.68	\$1.78
6/8/2016	\$1.60	\$1.77
6/9/2016	\$1.50	\$1.76
6/10/2016	\$1.37	\$1.74
6/13/2016	\$1.26	\$1.72
6/14/2016	\$1.33	\$1.70
6/15/2016	\$1.71	\$1.70
6/16/2016	\$1.63	\$1.70
6/17/2016	\$1.69	\$1.70
6/20/2016	\$1.62	\$1.70
6/21/2016	\$1.53	\$1.69
6/22/2016	\$1.56	\$1.69
6/23/2016	\$1.67	\$1.69
6/24/2016	\$1.54	\$1.68

Date	Closing Price	Average Closing Price
6/27/2016	\$1.41	\$1.67
6/28/2016	\$1.47	\$1.67
6/29/2016	\$1.51	\$1.66
6/30/2016	\$1.49	\$1.66
7/1/2016	\$1.58	\$1.65
7/5/2016	\$1.47	\$1.65
7/6/2016	\$1.54	\$1.65
7/7/2016	\$1.65	\$1.65
7/8/2016	\$1.67	\$1.65
7/11/2016	\$1.62	\$1.65
7/12/2016	\$1.61	\$1.65
7/13/2016	\$1.58	\$1.64
7/14/2016	\$1.55	\$1.64
7/15/2016	\$1.51	\$1.64
7/18/2016	\$1.51	\$1.64
7/19/2016	\$1.48	\$1.63
7/20/2016	\$1.53	\$1.63
7/21/2016	\$1.49	\$1.63
7/22/2016	\$1.46	\$1.62
7/25/2016	\$1.47	\$1.62
7/26/2016	\$1.44	\$1.62
7/27/2016	\$1.55	\$1.62
7/28/2016	\$1.47	\$1.61
7/29/2016	\$1.44	\$1.61
8/1/2016	\$1.47	\$1.61
8/2/2016	\$1.44	\$1.61
8/3/2016	\$1.49	\$1.60
8/4/2016	\$1.51	\$1.60
8/5/2016	\$1.53	\$1.60
8/8/2016	\$1.54	\$1.60
8/9/2016	\$1.58	\$1.60

The date of purchase or sale is the “contract” or “trade” date as distinguished from the “settlement” date. All purchase, acquisition, and sale prices shall exclude any fees and commissions. The receipt or grant by gift, devise or operation of law of Aegerion publicly traded common stock during the Class Period shall not be deemed a purchase or sale of Aegerion publicly traded common stock for the calculation of a claimant’s recognized claim, nor shall it be deemed an assignment of any claim relating to the purchase of such shares unless specifically provided in the instrument of gift or assignment. The receipt of Aegerion publicly traded common stock during the Class Period in exchange for securities of any other corporation or entity shall not be deemed a purchase or sale of Aegerion publicly traded common stock.

For Class Members who held Aegerion publicly traded common stock at the beginning of the Class Period or made multiple purchases, acquisitions, or sales during the Class Period, the First-In, First-Out (“FIFO”) method will be applied to such holdings, purchases, acquisitions, and sales for purposes of calculating a claim. Under the FIFO method, sales of Aegerion publicly traded common stock during the Class Period will be matched, in chronological order, first against shares of common stock held at the beginning of the Class Period. The remaining sales of common stock during the Class Period will then be matched, in chronological order, against common stock purchased or acquired during the Class Period.

A Class Member will be eligible to receive a distribution from the Net Settlement Fund only if a Class Member had a net overall loss, after all profits from transactions in all Aegerion common stock described above during the Class Period are subtracted from all losses. However, the proceeds from sales of common stock that have been matched against the common stock held at the beginning of the Class Period will not be used in the calculation of such net loss. No distributions will be made to Authorized Claimants who would otherwise receive a distribution of less than \$10.00.

Payment pursuant to the Plan of Allocation set forth above shall be conclusive against all Authorized Claimants. Defendants, their respective counsel, and all other Released Persons will have no responsibility or liability

whatsoever for the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. No Person shall have any claim against Lead Plaintiffs, Lead Plaintiffs' Counsel, the Claims Administrator, or other Person designated by Lead Counsel, Defendants, or Defendants' counsel based on distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. All Class Members who fail to complete and submit a valid and timely Proof of Claim shall be barred from participating in distributions from the Net Settlement Fund (unless otherwise ordered by the Court), but otherwise shall be bound by all of the terms of the Stipulation, including the terms of any judgment entered and the releases given.

Please contact the Claims Administrator or Lead Counsel if you disagree with any determinations made by the Claims Administrator regarding your Proof of Claim. If you are unsatisfied with the determinations, you may ask the Court, which retains jurisdiction over all Class Members and the claims administration process, to decide the issue by submitting a written request.

Defendants, their respective counsel, and all other Released Persons will have no responsibility or liability whatsoever for the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. Lead Plaintiffs and Lead Plaintiffs' Counsel, likewise, will have no liability for their reasonable efforts to execute, administer, and distribute the Settlement.

Distributions will be made to Authorized Claimants after all claims have been processed and after the Court has finally approved the Settlement. If any funds remain in the Net Settlement Fund by reason of un-cashed distribution checks or otherwise, then, after the Claims Administrator has made reasonable and diligent efforts to have Class Members who are entitled to participate in the distribution of the Net Settlement Fund cash their distributions, any balance remaining in the Net Settlement Fund after at least six (6) months after the initial distribution of such funds shall be used: (a) first, to pay any amounts mistakenly omitted from the initial disbursement; (b) second, additional settlement administration fees, costs, and expenses, including those of Lead Plaintiffs' Counsel as may be approved by the Court; and (c) to make a second distribution to claimants who cashed their checks from the initial distribution and who would receive at least \$10.00, after payment of the estimated costs, expenses, or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. These redistributions shall be repeated, if economically feasible, until the balance remaining in the Net Settlement Fund is *de minimis* and such remaining balance shall then be distributed to an appropriate non-sectarian, non-profit charitable organization serving the public interest selected by Lead Counsel and approved by the Court.

#### **SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES**

If you purchased or acquired Aegerion publicly traded common stock during the Class Period for the beneficial interest of an individual or organization other than yourself, the Court has directed that, WITHIN SEVEN (7) DAYS OF YOUR RECEIPT OF THIS NOTICE, you either (a) provide to the Claims Administrator the name and last known address of each person or organization for whom or which you purchased or acquired such securities during such time period, or (b) request additional copies of this Notice and the Proof of Claim form, which will be provided to you free of charge, and within ten (10) days mail the Notice and Proof of Claim form directly to the beneficial owners of the securities referred to herein. If you choose to follow alternative procedure (b), upon such mailing, you must send a statement to the Claims Administrator confirming that the mailing was made as directed and retain the names and addresses for any future mailings to Class Members. You are entitled to reimbursement from the Settlement Fund of your reasonable expenses actually incurred in connection with the foregoing, including reimbursement of postage expense and the cost of ascertaining the names and addresses of beneficial owners. Your reasonable expenses will be paid upon request and submission of appropriate supporting documentation. All communications concerning the foregoing should be addressed to the Claims Administrator:

*Aegerion Securities Litigation*  
Claims Administrator  
c/o Gilardi & Co. LLC  
P.O. Box 30253  
College Station, TX 77842-3253  
[www.aegerionsecuritieslitigation.com](http://www.aegerionsecuritieslitigation.com)

DATED: June 29, 2017

BY ORDER OF THE COURT  
UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS